Home » Stocks » DFFN

Diffusion Pharmaceuticals, Inc. (DFFN)

Stock Price: $1.07 USD 0.03 (2.88%)
Updated Jan 20, 2021 4:00 PM EST - Market closed
After-hours: $1.11 +0.04 (3.74%) Jan 20, 7:57 PM
Market Cap 69.14M
Revenue (ttm) n/a
Net Income (ttm) -15.83M
Shares Out 64.01M
EPS (ttm) -0.38
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 20
Last Price $1.07
Previous Close $1.04
Change ($) 0.03
Change (%) 2.88%
Day's Open 1.04
Day's Range 1.04 - 1.25
Day's Volume 4,682,564
52-Week Range 0.26 - 1.50

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

CHARLOTTESVILLE, Va., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), today announced that the Company is participating in the H...

GlobeNewsWire - 2 months ago

Initiated and Advanced C linical Trial Evaluating Lead Product Candidate in COVID-19 Patients

GlobeNewsWire - 3 months ago

CHARLOTTESVILLE, Va., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), today announced the appointment of Christopher D. Galloway...

GlobeNewsWire - 3 months ago

CHARLOTTESVILLE, Va., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (N asdaq : DFFN) (“Diffusion” or “the Company”) today announced the appointment of William Elder, J.D....

GlobeNewsWire - 4 months ago

CHARLOTTESVILLE, Va., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), today announced its management will present at the H.C....

GlobeNewsWire - 4 months ago

CHARLOTTESVILLE, Va., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), today announced that Robert (“Bob”) J. Cobuzzi Jr., Ph....

GlobeNewsWire - 4 months ago

Romanian Regulatory Approval Received to Begin Phase 1b COVID-19 Clinical Trial Romanian Regulatory Approval Received to Begin Phase 1b COVID-19 Clinical Trial

GlobeNewsWire - 5 months ago

Continues global clinical development of TSC for the treatment of COVID-19 Continues global clinical development of TSC for the treatment of COVID-19

Benzinga - 5 months ago

Diffusion Pharmaceuticals (NASDAQ: DFFN) shares are trading lower on Monday after the company received guidance from the FDA on the company's IND for trans sodium crocetinate in Covid-19 patie...

GlobeNewsWire - 5 months ago

Guidance being incorporated into global study protocol Enrollment of first patient now expected in August

GlobeNewsWire - 6 months ago

Phase 1b dosing expected to begin this month  Data read-out expected later this quarter

GlobeNewsWire - 7 months ago

Dosing expected to begin in Q2 2020 with first data in Q3 2020 Trial expected to enroll 224 patients over 12 months, with 24 patients immediately U.S. IND filing planned for later this month D...

GlobeNewsWire - 7 months ago

Share price exceeds $1 at closing for 10 consecutive trading days Share price exceeds $1 at closing for 10 consecutive trading days

24/7 Wall Street - 7 months ago

Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) shares pushed higher to start the week after the company announced a critical update from the U.S.

GlobeNewsWire - 8 months ago

CHARLOTTESVILLE, Va., May 20, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), a cutting-edge biotechnology company developing new treat...

GlobeNewsWire - 8 months ago

Inclusion in FDA’s Coronavirus Treatment Acceleration Program significantly shortens regulatory review cycles

Benzinga - 9 months ago

Diffusion Pharmaceuticals Inc (NASDAQ: DFFN) shares were more than doubling Wednesday following an announcement by the company regarding testing of its lead asset for COVID-19-related complica...

GlobeNewsWire - 9 months ago

Partnering with University of Virginia Health and iTHRIV Partnering with University of Virginia Health and iTHRIV

GlobeNewsWire - 9 months ago

Overtaxed healthcare systems will delay enrollment in some geographic locations Overtaxed healthcare systems will delay enrollment in some geographic locations

GlobeNewsWire - 10 months ago

Dr. Gainer to remain on board of directors Dr. Gainer to remain on board of directors

GlobeNewsWire - 11 months ago

CHARLOTTESVILLE, Va., Feb. 07, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or “the Company”), a cutting-edge biotechnology company developing new trea...

GlobeNewsWire - 1 year ago

CHARLOTTESVILLE, Va., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion,” the “Company,” “we,” “our” or “us”), a cutting-edge biotechnology company ...

GlobeNewsWire - 1 year ago

CHARLOTTESVILLE, Va., Dec. 13, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion,” the “Company,” “we,” “our” or “us”) today announced the closing of its pre...

GlobeNewsWire - 1 year ago

CHARLOTTESVILLE, Va., Dec. 12, 2019 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), please note that the prici...

GlobeNewsWire - 1 year ago

Presentation Made by Chief Scientific Officer John Gainer at the Inaugural Glioblastoma Drug Development Summit Presentation Made by Chief Scientific Officer John Gainer at the Inaugural Gliob...

Seeking Alpha - 1 year ago

Diffusion Pharmaceuticals is a tiny micro-cap with market cap between $4.6m and $11.1m (based on a price of $0.285), developing an add-on treatment for brain cancer (glioblastoma) and stroke.

GlobeNewsWire - 1 year ago

Chief Scientific Officer Dr. John Gainer to Present at Inaugural Glioblastoma Drug Development Summit Chief Scientific Officer Dr. John Gainer to Present at Inaugural Glioblastoma Drug Develop...

GlobeNewsWire - 1 year ago

CHARLOTTESVILLE, Va., Nov. 15, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion,” the “Company,” “we,” “our” or “us”) a clinical-stage biotechnology company...

GlobeNewsWire - 1 year ago

CHARLOTTESVILLE, Va., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or the “Company”), a clinical-stage biotechnology company developing new tr...

GlobeNewsWire - 1 year ago

CHARLOTTESVILLE, Va., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening med...

GlobeNewsWire - 1 year ago

CHARLOTTESVILLE, Va., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening me...

Forbes - 1 year ago

Year to date, the market has gifted investors a 9.92% return, but it remains off 5.73% from the start of the fourth quarter. While many investors are enjoying a lift in their stocks, the Ben G...

Other stocks mentioned: ECOR, SPEX

About DFFN

Diffusion Pharmaceuticals, a clinical stage biotechnology company, develops treatments for life-threatening medical conditions. Its lead product candidate is transcrocetinate sodium, which is in Phase III trials for the treatment of glioblastoma multiforme (GBM); Phase II clinical trials for the treatment of metastatic brain cancer; and Phase II trial for the treatment of acute stroke. The company is also developing RES-529, a PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for the treatment of age-related macul... [Read more...]

Industry
Biotechnology
Founded
2001
Stock Exchange
NASDAQ
Ticker Symbol
DFFN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to one analyst, the rating for DFFN stock is "Hold" and the 12-month stock price forecast is 2.75.

Price Target
$2.75
Analyst Consensus: Hold